XTalks

DECEMBER 14, 2020

AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle. The identity of the facility was not disclosed.

Packaging 52

Packaging Packaging Drugs Generic Pharmaceutical 52

Pharmaceutical Technology

FEBRUARY 18, 2023

Novartis Overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It was under development for renal cell carcinoma as first line therapy.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

NOVEMBER 5, 2020

and Aavis Pharmaceuticals Inc. The product will be distributed by Jubilant Cadista, a unit of Jubilant Pharma Ltd. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. YARDLEY, Pa.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

Pharmaceutical Technology

DECEMBER 22, 2022

This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.

Insulin 130

Insulin Production Development Genetics 130

Pharmaceutical Technology

SEPTEMBER 23, 2022

For pharma and biotech companies, there are many advantages to partnering with a Contract Development and Manufacturing Organisations (CDMO): they can access more specialized knowledge, state-of-the-art equipment, and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market.

Manufacturing 147

Manufacturing Drugs Production Packaging 147

XTalks

JUNE 8, 2022

Biosimilars are generic versions of biologics medicines that already have regulatory approval (called the reference product) and have expired patents leading to a loss of exclusivity rights. Related: Cyltezo Becomes First FDA-Approved Interchangeable Humira Biosimilar.

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69

The Pharma Data

OCTOBER 27, 2020

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. A playback of the call will be archived and accessible on the same website for at least three months. About Lannett Company, Inc.

Generic Pharmaceutical 52

Generic Pharmaceutical Packaging Packaging Manufacturing 52

Pharma in Brief

DECEMBER 3, 2023

The listed patents must be addressed by the manufacturer of a generic or biosimilar drug before its drug can receive a Notice of Compliance ( NOC ) and be sold in Canada. The early-working exception allows generic or biosimilar manufacturers to work a patented invention “for uses reasonably related” to obtaining regulatory approval.

Regulation 52

Regulation Compliance Medicine Manufacturing 52

The Pharma Data

MAY 8, 2021

There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 2, 2021

There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

MAY 15, 2023

Yannis Skoufalos , former Global Product Supply Officer at Procter & Gamble between 2011 and 2019, a US-headquartered consumer goods company with approximately USD 81 billion in sales for the year ending in March 2023. Nor can there be any guarantee that such products will be commercially successful in the future.

Sales 40

Sales Production Doctors Doctor 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion the drug generated in 2021. every eight weeks for the 90 mg dose, according to the manufacturer. Pfizer Inc. mg tables.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

FDA Law Blog

JANUARY 24, 2024

If this vision is achieved, the United States can bring innovative biotechnologies and products to markets faster while building a more robust supply chain ecosystem. That’s a pretty lofty API manufacturing goal, but one that the API Innovation Center (“APIIC”) was charged to take up, consider, and propose some possible solutions.

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report.

Production 263

Production Manufacturing Generic Drugs Drugs 263

The Pharma Data

DECEMBER 23, 2020

During this global health crisis response, we must establish partners with the strongest capabilities, like Aurobindo, to expand the manufacturing and delivery of our vaccine. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612.

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. Aurobindo will manufacture the finished doses at its facilities in Hyderabad.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52